Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 15, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 25, 2005.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the share repurchase price of 1,565.53 pence per share.
Material Changes
- Share Repurchase: On March 15, 2006, the company purchased 635,000 ordinary shares of 25 pence each.
- Treasury Holdings: Following this transaction, the total number of shares held in Treasury increased to 151,169,678.
- Shares in Issue: The number of shares in issue (excluding Treasury shares) stands at 5,821,225,828.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (151,169,678) against subsequent filings.
- Confirm the total shares in issue (5,821,225,828) to assess dilution or capital structure changes.
- Review the Annual General Meeting minutes from May 25, 2005, to understand the full scope of the share buyback authority.